Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
NCT ID: NCT01360879
Last Updated: 2011-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2010-09-30
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
NCT01360892
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
NCT06779058
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
NCT01671046
ShearWave™ Elastography to Assess Liver Fibrosis in Chinese Patients With Hepatitis B
NCT02313649
Assessment of Liver Fibrosis and Prognosis in Chinese Patients With CHB Infection Using STE/STQ Elastography
NCT03530657
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If in the hospital they can perform FibroScan®, FobroScan® also be performed. The subjects must be scheduled for liver biopsy either prior to treatment (treatment naïve) or, if previously treated, they must have been off treatment for at least six months. The time between the Real-time Tissue Elastography® , biopsy, blood sampling and FiroScan® must not exceed four weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic hepatitis B or Chronic hepatitis C
* Subject is willing to fast for 8 hours prior to each study visit
Exclusion Criteria
* Evidence or history of chronic hepatitis not caused by HBV or HCV
* During 6 months before registration to this trial has completed, nucleic acid analogue preparations or interferon therapy was performed.
* Pregnant or lactating patients
* Contraindications of liver biopsy or liver resection
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kindai University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masatoshi Kudo, Professor
Role: STUDY_CHAIR
Kinki University Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kinki University Faculty of Medicine
Ōsaka-sayama, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JLOG1002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.